T
Tuya Pal
Researcher at Vanderbilt University
Publications - 22
Citations - 2585
Tuya Pal is an academic researcher from Vanderbilt University. The author has contributed to research in topics: Genetic counseling & Genetic testing. The author has an hindex of 8, co-authored 22 publications receiving 1787 citations. Previous affiliations of Tuya Pal include Northwestern University & Moffitt Cancer Center.
Papers
More filters
Journal ArticleDOI
Genetic/familial high-risk assessment: breast and ovarian.
Mary B. Daly,Jennifer E. Axilbund,Saundra S. Buys,Beth Crawford,Carolyn Farrell,Susan Friedman,Judy Garber,Salil Goorha,Stephen B. Gruber,Heather Hampel,Virginia Kaklamani,Wendy Kohlmann,Allison W. Kurian,Jennifer K. Litton,P. Kelly Marcom,Robert L. Nussbaum,Kenneth Offit,Tuya Pal,Boris Pasche,Robert Pilarski,Gwen Reiser,Kristen M. Shannon,Jeffrey R. Smith,Elizabeth M. Swisher,Jeffrey N. Weitzel +24 more
TL;DR: Overview All cancers develop as a result of mutations in certain genes, such as those involved in the regulation of cell growth and/or DNA repair, but not all of these mutations are inherited from a parent.
Journal ArticleDOI
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017.
Mary B. Daly,Robert Pilarski,Michael Berry,Saundra S. Buys,Meagan Farmer,Susan Hatters Friedman,Judy Garber,Noah D. Kauff,Seema A. Khan,Catherine Klein,Wendy Kohlmann,Allison W. Kurian,Jennifer K. Litton,Lisa Madlensky,Sofia D. Merajver,Kenneth Offit,Tuya Pal,Gwen Reiser,Kristen M. Shannon,Elizabeth M. Swisher,Shaveta Vinayak,Nicoleta C. Voian,Jeffrey N. Weitzel,Myra J. Wick,Georgia L. Wiesner,Mary A. Dwyer,Susan Darlow +26 more
TL;DR: The NCCN Guidelines Insights summarize the panel's discussion and most recent recommendations regarding risk management for carriers of moderately penetrant genetic mutations associated with breast and/or ovarian cancer.
Journal ArticleDOI
Genetic/familial high-risk assessment: Breast, ovarian, and pancreatic, version 2.2021
Mary B. Daly,Tuya Pal,Michael Berry,Saundra S. Buys,Patricia I. Dickson,Susan M. Domchek,Ahmed Elkhanany,Susan Hatters Friedman,Michael Goggins,Mollie L. Hutton,Beth Y. Karlan,Seema A. Khan,Catherine Klein,Wendy Kohlmann,Allison W. Kurian,Christine Laronga,Jennifer K. Litton,Julie S. Mak,Carolyn S. Menendez,Sofia D. Merajver,Barbara S. Norquist,Kenneth Offit,Holly J. Pederson,Gwen Reiser,Leigha Senter-Jamieson,Kristen M. Shannon,Rebecca Shatsky,Kala Visvanathan,Jeffrey N. Weitzel,Myra J. Wick,Kari B. Wisinski,Matthew B. Yurgelun,Susan Darlow,Mary A. Dwyer +33 more
TL;DR: The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic focus primarily on assessment of pathogenic or likely pathogenic variants associated with increased risk of breast, ovarian, and pancreatic cancer and recommended approaches to genetic testing/counseling and management strategies as mentioned in this paper.
Journal ArticleDOI
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020.
Mary B. Daly,Robert Pilarski,Matthew B. Yurgelun,Michael Berry,Saundra S. Buys,Patricia I. Dickson,Susan M. Domchek,Ahmed Elkhanany,Susan Hatters Friedman,Judy Garber,Michael Goggins,Mollie L. Hutton,Seema A. Khan,Catherine Klein,Wendy Kohlmann,Allison W. Kurian,Christine Laronga,Jennifer K. Litton,Julie S. Mak,Carolyn S. Menendez,Sofia D. Merajver,Barbara S. Norquist,Kenneth Offit,Tuya Pal,Holly J. Pederson,Gwen Reiser,Kristen M. Shannon,Kala Visvanathan,Jeffrey N. Weitzel,Myra J. Wick,Kari B. Wisinski,Mary A. Dwyer,Susan Darlow +32 more
TL;DR: These NCCN Guidelines Insights summarize the panel's discussion and most recent recommendations regarding criteria for high-penetrance genes associated with breast and ovarian cancer beyond BRCA1/2, pancreas screening and genesassociated with pancreatic cancer, genetic testing for the purpose of systemic therapy decision-making, and testing for people with Ashkenazi Jewish ancestry.
Journal ArticleDOI
A Population-Based Study of Genes Previously Implicated in Breast Cancer
Chunling Hu,Steven N. Hart,Rohan Gnanaolivu,Hongyan Huang,Kun Y. Lee,Jie Na,Chi Gao,Jenna Lilyquist,Siddhartha Yadav,Nicholas J. Boddicker,Raed Samara,Josh Klebba,Christine B. Ambrosone,Hoda Anton-Culver,Paul L. Auer,Elisa V. Bandera,Leslie Bernstein,Kimberly A. Bertrand,Elizabeth S. Burnside,Brian D. Carter,Heather Eliassen,Susan M. Gapstur,Mia M. Gaudet,Christopher A. Haiman,James M. Hodge,David J. Hunter,David J. Hunter,Eric J. Jacobs,Esther M. John,Charles Kooperberg,Allison W. Kurian,Loic Le Marchand,Sara Lindstroem,Tricia Lindstrom,Huiyan Ma,Susan L. Neuhausen,Polly A. Newcomb,Katie M. O'Brien,Janet E. Olson,Irene M. Ong,Tuya Pal,Julie R. Palmer,Alpa V. Patel,Sonya Reid,Lynn Rosenberg,Dale P. Sandler,Christopher G. Scott,Rulla M. Tamimi,Jack A. Taylor,Amy Trentham-Dietz,Celine M. Vachon,Clarice R. Weinberg,Song Yao,Argyrios Ziogas,Jeffrey N. Weitzel,David E. Goldgar,Susan M. Domchek,Katherine L. Nathanson,Peter Kraft,Eric C. Polley,Fergus J. Couch +60 more
TL;DR: In this paper, population-based estimates of the risk of breast cancer associated with germline pathogenic variants in cancer-predisposition genes are critically needed for risk assessment and risk assessment.